Mark S. Slaughter, M.D., Joseph G. Rogers, M.D., Carmelo A. Milano, M.D., Stuart D. Russell, M.D., John V. Conte, M.D., David Feldman, M.D., Ph.D., Benjamin Sunlight, M.D., Antone J. Tatooles, M.D., Reynolds M. Delgado, III, M.D., James W. Long, M.D., Ph.D., Thomas C. Wozniak, M.D., Waqas Ghumman, M.D., David J. Farrar, Ph.D., and O. Howard Frazier, M.D. For the HeartMate II Investigators: Advanced Heart Failure Treated with Continuous-Movement Remaining Ventricular Assist Device.4282, which authorizes Part D programs to suspend payment of promises to pharmacies suspected of a credible allegation of fraud. While we remain analyzing these provisions in detail, we are gratified to observe they are section of the larger discussion on improving patient health and making sure the integrity of our health care system. They are issues that AMCP has used the lead on for years. In the arriving weeks, we will be offering lawmakers on the Committee in-depth tips about how these proposals may be modified to have the biggest positive impact.